• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    BriaCell Therapeutics Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    6/18/25 8:27:34 AM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BCTX alert in real time by email
    false 0001610820 0001610820 2025-06-16 2025-06-16 0001610820 BCTX:CommonSharesNoParValueMember 2025-06-16 2025-06-16 0001610820 BCTX:WarrantsToPurchaseCommonSharesNoParValueMember 2025-06-16 2025-06-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): June 16, 2025

     

    BRIACELL THERAPEUTICS CORP.

    (Exact name of registrant as specified in its charter)

     

    British ColumbiaA1   47-1099599

    (State or other jurisdiction

    of incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

     

    Suite 300 - 235 15th Street

    West Vancouver, BC V7T 2X1

      V7T 2X1
    (Address of principal executive offices)   (Zip Code)

     

    (604) 921-1810

    (Registrant’s telephone number, including area code)

     

    Commission File No. 001-40101

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered under Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Shares, no par value   BCTX   The Nasdaq Stock Market LLC
    Warrants to purchase common shares, no par value   BCTXW   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 7.01 Regulation FD Disclosure.

     

    On June 16, 2025, BriaPro Therapeutics Corp., a two-third (2/3) owned subsidiary of BriaCell Therapeutics Corp. (the “Company”), filed its unaudited condensed interim consolidated financial statements and management’s discussion and analysis for the three and nine month period ended April 30, 2025, with the British Columbia Securities Commission and Alberta Securities Commission. A copy of the condensed interim consolidated financial statements and management’s discussion and analysis for the three and nine month period ended April 30, 2025 are included as Exhibit 99.1 and Exhibit 99.2 to this Current Report on Form 8-K and are incorporated herein by reference.

     

    The information furnished pursuant to this Item 7.01, including Exhibit 99.1 and Exhibit 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933 (the “Securities Act”) or the Exchange Act, regardless of any general incorporation language in such filings.

     

    Item 9.01 Condensed interim financial statements and Exhibits

     

    EXHIBIT INDEX

     

    Exhibit No.    
    99.1   BriaPro Therapeutics Corp. Unaudited Condensed interim consolidated financial statements for the three and nine month period ended April 30, 2025.
    99.2   BriaPro Therapeutics Corp. Management’s Discussion and Analysis for the three and nine month period ended April 30, 2025.
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      BRIACELL THERAPEUTICS CORP.
       
      /s/ William V. Williams
    June 17, 2025 William V. Williams
      President and Chief Executive Officer

     

     

     

    Get the next $BCTX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BCTX

    DatePrice TargetRatingAnalyst
    2/14/2022$25.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BCTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. initiated coverage on BriaCell Therapeutics with a new price target

      HC Wainwright & Co. initiated coverage of BriaCell Therapeutics with a rating of Buy and set a new price target of $25.00

      2/14/22 6:04:45 AM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Lustig Marc bought $2,000,001 worth of shares (902,935 units at $2.21) (SEC Form 4)

      4 - BriaCell Therapeutics Corp. (0001610820) (Issuer)

      5/20/24 4:00:14 PM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Bondarenko Jamieson bought $128,240 worth of shares (28,000 units at $4.58), increasing direct ownership by 20% to 169,856 units

      4 - BriaCell Therapeutics Corp. (0001610820) (Issuer)

      12/28/22 4:38:08 PM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Williams William V.

      4 - BriaCell Therapeutics Corp. (0001610820) (Issuer)

      12/28/22 3:22:52 PM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCTX
    Financials

    Live finance-specific insights

    See more
    • ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2023

      The Company achieved revenue of $20.7 million during the year ended April 30, 2023, a 6.7% increase from the year ended April 30, 2022. YoY growth increases to 9.0% when adjusting for the effects of currency translation. The Company recorded total revenue of $5.6 million during the three months ended April 30, 2023, the highest quarterly revenue total the Company has recorded. IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, today announced financial results for the full fiscal year 2023 ended April 30, 2023. "As we usher in Fiscal Year 2024, we carry with us a strong momentum from the impressive

      7/7/23 8:10:00 AM ET
      $BCTX
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCTX
    SEC Filings

    See more
    • BriaCell Therapeutics Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - BriaCell Therapeutics Corp. (0001610820) (Filer)

      6/18/25 8:27:34 AM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by BriaCell Therapeutics Corp.

      10-Q - BriaCell Therapeutics Corp. (0001610820) (Filer)

      6/16/25 4:34:51 PM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by BriaCell Therapeutics Corp.

      SCHEDULE 13G/A - BriaCell Therapeutics Corp. (0001610820) (Subject)

      5/13/25 9:08:52 PM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven

      Together, Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven add 30 satellite locations to enroll patients in BriaCell's pivotal Phase 3 studyBriaCell's Phase 3 study currently has 58 active clinical sites across 15 states, including Smilow Cancer Hospital, Los Angeles Cancer Network, University of Arizona, DHR Health Oncology Institute, Sylvester Comprehensive Cancer Center, Cancer Care Northwest, Hematology Oncology Associates of Fredericksburg, Northwestern University, Manhattan Hematology/Oncology Associates, New York Cancer & Blood Specialists, and Texas Oncology-Baylor Charles A. Sammons Cancer Center PHILADELPHIA and VANCOUVER, British Columbia, July 02, 2025 (

      7/2/25 7:30:56 AM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer

      Independent DSMB identifies no safety concerns, and recommends continuation of BriaCell's pivotal Phase 3 study of Bria-IMT™ plus immune check point inhibitor Review marks third consecutive positive recommendation by DSMBStudy is being conducted under FDA Fast Track Designation PHILADELPHIA and VANCOUVER, British Columbia, June 24, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to report that the independent Data Safety Monitoring Board (DSMB) has completed its third scheduled safety data review of Bria

      6/24/25 7:30:25 AM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26

      PHILADELPHIA and VANCOUVER, British Columbia, June 04, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ)), (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces today that the Company will be conducting two virtual investor presentations on Thursday, June 12, at 12:00 PM EDT and on Thursday, June 26, at 12:00 PM EDT, arranged by Renmark Financial Communications Inc. Briacell Therapeutics Corp. welcomes stakeholders, investors, and other individual followers to register and attend these live events. Investors interested in participating in this event will need to re

      6/4/25 7:30:50 AM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Lustig Marc bought $2,000,001 worth of shares (902,935 units at $2.21) (SEC Form 4)

      4 - BriaCell Therapeutics Corp. (0001610820) (Issuer)

      5/20/24 4:00:14 PM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCTX
    Leadership Updates

    Live Leadership Updates

    See more
    • BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

      PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general meeting of shareholders of the Company (the "Shareholders") for the year ended July 31, 2024 held on February 5, 2025 (the "Meeting"). A total of 36.26% of the Company's issued and outstanding common shares (the "Common Shares") were voted at the Meeting. At the Meeting, the Shareholders overwhelmingly voted in favour of all proposed resolutions, consisting of

      2/5/25 6:15:47 PM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025

      PHILADELPHIA and VANCOUVER, British Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the Company's Annual General Meeting of Shareholders (the "Meeting"), which was originally scheduled to be held on Thursday, January 23, 2025, has been rescheduled. The Meeting is now scheduled to be held on Wednesday, February 5, 2025, at 9:00 a.m. (ET) at Suite 3400, One First Canadian Place, Toronto, ON, M5X 1A4. The record date for the Meeting, December 9, 2024, is unchanged and applies to the postponed

      1/3/25 5:05:00 PM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BriaCell Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures

      PHILADELPHIA and VANCOUVER, British Columbia, Dec. 17, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the Company will be relying on, and has satisfied all of the conditions to rely on, CSA Coordinated Blanket Order 51-931 for exemption from the requirements to send proxy-related materials (the "Meeting Materials") for its upcoming annual general meeting (the "Meeting") to be held on Thursday, January 23, 2025, at Suite 3400, One First Canadian Place, Toronto, ON, M5X 1A4. at 10:00 a.m. (EST) due to the susp

      12/17/24 4:05:59 PM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by BriaCell Therapeutics Corp.

      SC 13D/A - BriaCell Therapeutics Corp. (0001610820) (Subject)

      12/12/24 6:06:07 AM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by BriaCell Therapeutics Corp.

      SC 13D/A - BriaCell Therapeutics Corp. (0001610820) (Subject)

      12/10/24 6:06:45 AM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by BriaCell Therapeutics Corp.

      SC 13D/A - BriaCell Therapeutics Corp. (0001610820) (Subject)

      12/5/24 7:45:06 AM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care